CA2295316A1 - Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy - Google Patents

Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy Download PDF

Info

Publication number
CA2295316A1
CA2295316A1 CA002295316A CA2295316A CA2295316A1 CA 2295316 A1 CA2295316 A1 CA 2295316A1 CA 002295316 A CA002295316 A CA 002295316A CA 2295316 A CA2295316 A CA 2295316A CA 2295316 A1 CA2295316 A1 CA 2295316A1
Authority
CA
Canada
Prior art keywords
diagnostic
prophylactic
therapy
manufacture
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002295316A
Other languages
French (fr)
Other versions
CA2295316C (en
Inventor
Joann A. Suzich
Michael P. Mccarthy
Robert C. Rose
Robert L. Garcea
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
University of Technology Corp
University of Rochester
Original Assignee
University Of Colorado, University Technology Corporation
University Of Rochester
Medimmune, Inc.
Joann A. Suzich
Michael P. Mccarthy
Robert C. Rose
Robert L. Garcea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Colorado, University Technology Corporation, University Of Rochester, Medimmune, Inc., Joann A. Suzich, Michael P. Mccarthy, Robert C. Rose, Robert L. Garcea filed Critical University Of Colorado, University Technology Corporation
Publication of CA2295316A1 publication Critical patent/CA2295316A1/en
Application granted granted Critical
Publication of CA2295316C publication Critical patent/CA2295316C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to stable HPV capsomeres which express at least one virus-neutralizing conformational epitope of a native HPV L1 protein which are substantially incapable of assembly into virus-like particles. These capsomeres, because of their smaller size, and immunogenic properties are well suited for use in HPV vaccines and as diagnostic agents. Moreover, because of their smaller size (relative to VLPs), these stable capsomeres may be easily purified and should result in HPV vaccines of enhanced homogeneity.
CA002295316A 1997-07-03 1998-07-02 Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy Expired - Fee Related CA2295316C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88805097A 1997-07-03 1997-07-03
US08/888,050 1997-07-03
PCT/US1998/013799 WO1999001557A1 (en) 1997-07-03 1998-07-02 Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Publications (2)

Publication Number Publication Date
CA2295316A1 true CA2295316A1 (en) 1999-01-14
CA2295316C CA2295316C (en) 2007-06-26

Family

ID=25392417

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295316A Expired - Fee Related CA2295316C (en) 1997-07-03 1998-07-02 Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Country Status (5)

Country Link
EP (1) EP1000157A1 (en)
JP (1) JP2002510976A (en)
AU (1) AU755679B2 (en)
CA (1) CA2295316C (en)
WO (1) WO1999001557A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437951A (en) 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US6228368B1 (en) * 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
AU3730600A (en) * 1999-03-18 2000-10-04 Xiaojiang Chen Compositions preparations and uses of human papillomavirus l1 protein
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
AU2003219760A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of virus-like particles for expression in insect cells
US7425438B2 (en) 2002-10-17 2008-09-16 Bioleaders Corporation Vector for anti-HPV vaccine and transformed microorganism by the vector
ATE474596T1 (en) 2004-09-10 2010-08-15 Asahi Glass Co Ltd VACCINE AGAINST HUMAN PAPILLOMAVIRUS FOR ORAL ADMINISTRATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000018I1 (en) * 1991-07-19 2007-05-24 Univ Queensland Polynucleotide portion of the HPV16 genome
ES2294778T3 (en) * 1992-06-25 2008-04-01 Georgetown University VACCINES FOR PAPILOMA VIRUS.
US6066324A (en) * 1994-10-07 2000-05-23 Loyola University Of Chicago Carboxyl terminal of papilloma virus L1 region is not required for formation of virus-like particles

Also Published As

Publication number Publication date
AU8284298A (en) 1999-01-25
JP2002510976A (en) 2002-04-09
CA2295316C (en) 2007-06-26
WO1999001557A1 (en) 1999-01-14
EP1000157A1 (en) 2000-05-17
AU755679B2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
DE122011100018I1 (en) Preparation of human papilloma virus capsid protein and virus-like particles.
BR9812139A (en) Vaccine
WO1999033868A3 (en) Human papillomavirus vaccine
JP2009102327A (en) Papilloma virus-like particle, fusion protein and method for producing the same
IL190554A0 (en) Papilloma virus capsomere vaccine formulations and methods of use
MY139031A (en) Vaccine composition comprising virus-like particles of human papillomavirus
WO2004000351A8 (en) Packaged virus-like particles for use as adjuvants: method of preparation and use
ES2150595T3 (en) PREPARATION PROCEDURE OF A VIRAL VECTOR OF AT LEAST 20 KB BY INTERMOLECULAR HOMOLOGICAL RECOMBINATION IN A PROCARIOT CELL.
PL317234A1 (en) Vaccines against papilloma virus
CA2143845A1 (en) Self-assembling recombinant papillomavirus capsid proteins
WO2003024481A3 (en) Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
AU2001270678A1 (en) Vaccine against foot-and-mouth disease
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
EP0232798A3 (en) Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
CA2229955A1 (en) Papilloma virus capsomere vaccine formulations and methods of use
CA2295316A1 (en) Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy
MY144492A (en) Human papillomavirus vaccine comprising hpv 16 and hpv 18 virus like particles, which induce cross protection against other hpv types
HUP9801334A2 (en) Dna encoding human papilloma virus type 18
WO2002024897A3 (en) Conditionally replicating viral vectors and their use
WO2002078631A3 (en) Improved conditionally replicating vectors for inhibiting viral infections
ATE344052T1 (en) PROTEIN DELIVERY SYSTEM USING PARTICLES SIMILAR TO HUMAN PAPILLOMA VIRUS.
AU1955001A (en) In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
CA2256696A1 (en) Modified small rna viruses

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150702